TQ0039 |
(±)-Zanubrutinib
|
1633350-06-7
|
98%
|
|
(±)-Zanubrutinib is a specific, potent and orally available Btk inhibitor.
|
T10240 |
ACP-5862
|
2230757-47-6
|
98%
|
|
ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective ...
|
T12673L |
PF-06250112
|
1609465-89-5
|
98%
|
|
PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase an...
|
T12152 |
N-piperidine Ibrutinib hydrochloride
|
2231747-18-3
|
98%
|
|
N-piperidine Ibrutinib hydrochloride is an potent inhibitor of BTK (WT BTK and C481S BTK with IC50s of 51.0 and 30.7 nM, respectively).
|
T14357 |
Spebrutinib besylate
|
1360053-81-1
|
98%
|
|
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).
|
T14956 |
CHMFL-BTK-01
|
2095280-64-9
|
98%
|
|
CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.
|
T16853 |
SB-633825
|
956613-01-7
|
98%
|
|
SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, 1...
|
T11379 |
GDC-0834
|
1133432-49-1
|
98%
|
|
GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and r...
|
T9814 |
JAK3/BTK-IN-1
|
2674036-91-8
|
98%
|
|
JAK3/BTK-IN-1 is a potent inhibitor of JAK3 / BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signal...
|
T35330 |
BTK inhibitor 1 (Compound 27)
|
2230724-66-8
|
98%
|
|
BTK inhibitor 1 (compound 27) is an inhibitor ofBTKwith an IC50 of 0.11 nM for Btk and inhibits B cell activation in hWB with an IC50 of 2 nM.
|
T15365 |
G-744
|
1346669-54-2
|
98%
|
|
G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthriti...
|
T16441 |
PCI-33380
|
1022899-36-0
|
98%
|
|
PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
|
T16265 |
Naluzotan
|
740873-06-7
|
98%
|
|
Naluzotan is an effective and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM. Naluzotan is used for the treatment of anxiety...
|
TQ0236 |
Tirabrutinib
|
1351636-18-4
|
98%
|
|
Tirabrutinib (ONO-4059) is a highly specific and orally bioavailable BTK inhibitor (IC50: 2.2 nM).
|
T13564 |
AZ7550
|
1421373-99-0
|
98%
|
|
AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
|
T9705 |
TL-895
|
1415823-49-2
|
98%
|
|
TL-895 is an ATP-competitive, and highly selective irreversible inhibitor of Bruton’s Tyrosine Kinase(BTK). TL-895 showed good potency with an IC50 of 1.5 nM and...
|
T14692 |
BMX-IN-1
|
1431525-23-3
|
98%
|
|
BMX-IN-1 is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine kinase (BTK, IC50 = 10.4 nM...
|
T9813 |
JAK3/BTK-IN-2
|
2674036-93-0
|
98%
|
|
JAK3/BTK-IN-2 is a potent inhibitor of JAK3 / BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signal...
|
T2603 |
Spebrutinib
|
1202757-89-8
|
97.14%
|
|
Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
|
T4268 |
CHMFL-BMX-078
|
1808288-51-8
|
98%
|
|
CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
|